Siemens Healthineers and Greenville-based Prisma Health are expanding their Value Partnership to enhance cancer care in South Carolina and Tennessee. As part of a USD 50 million investment, Prisma Health will acquire the Ethos adaptive radiotherapy system from Varian, a Siemens Healthineers company. This advanced AI-powered technology enables real-time adjustments to treatment plans, tailoring therapy to tumor and anatomical changes while minimizing damage to surrounding healthy tissue—offering patients more precise, personalized care.
In 2021, Siemens Healthineers and Prisma Health entered into a 10-year value partnership to improve care, promote innovation, and develop the local workforce. The expanded relationship will integrate next-generation technology and specialized clinical oncology and professional services, new tools and time-saving workflows. The goal of the Value Partnership is to advance more personalized, efficient, and accessible care for the communities Prisma Health serves.
Suggested Reading: Vivek Kanade Highlights Siemens Healthineers’ Vision for MEA.
“Since entering into the Value Partnership with Siemens Healthineers, Prisma Health has expanded access to imaging services and introduced new technologies and care locations to better serve our communities,” said Clarence Sevillian, executive vice president and chief operating officer of Prisma Health. “Our priority is ensuring that patients have access to care that is both compassionate and informed by the latest clinical insights. This next phase of the partnership reflects a continued spirit of collaboration, integrating advanced oncology tools and support services that may help streamline operations and enhance the patient experience.”
Added John Kowal, president and head of the Americas at Siemens Healthineers: “Working with Prisma Health to establish a full continuum of cancer care—from screening and diagnosis through survivorship—is an enormous point of pride for our organization. Combining the power of diagnostic imaging, radiation therapy, and post-treatment monitoring with professional services to manage complex oncology operations helps to ensure that advances in patient care are consistent and sustainable over time.”
